← All organizations
Highest phase reached
Phase 3
First clinical trial
Aug 1, 2006Last known activity
Aug 1, 2024
Timeline
1990s
- Jun 1, 1999
Genexine, Inc.— Founded
2010s
- Feb 13, 2019
Argos Therapeutics— Acquired
Drugs by trial phase (28 distinct, 48 trials)
Phase 3 (4 own, 1 via acquisition)
Phase 2 (9 own, 3 via acquisition)
Phase 1 (6 own, 1 via acquisition)
Other trials (3 own, 1 via acquisition)
Indications
Studied for
- Anemia
- Autoimmune Diseases
- Carcinoma in Situ
- Cervical Intraepithelial Neoplasia
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Dwarfism, Pituitary
- Endocrine System Diseases
- Glioblastoma
- Head and Neck Neoplasms
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- Hepatitis, Chronic
- HIV Infections
- Infections
- Kidney Diseases
- Neoplasms
- Renal Insufficiency, Chronic
- Triple Negative Breast Neoplasms
- Uterine Cervical Neoplasms
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (49)
- NCT04289155Lead sponsorN/A—
- NCT06490939Lead sponsorPhase 1Aug 1, 2024
- NCT06466785CollaboratorPhase 3Jan 25, 2024
- NCT06466785OfficialPhase 3Jan 25, 2024
- NCT06466785Lead sponsorPhase 3Jan 25, 2024
- NCT05191784Study directorPhase 2Jan 26, 2022
- NCT05191784Lead sponsorPhase 2Jan 26, 2022
- NCT05067946Lead sponsorPhase 2/Phase 3Oct 31, 2021
- NCT05067946Study directorPhase 2/Phase 3Oct 31, 2021
- NCT04915989Lead sponsorPhase 1Feb 16, 2021
- NCT04730427Lead sponsorPhase 1Jan 31, 2021
- NCT04730427Study directorPhase 1Jan 31, 2021
- NCT04715997Study directorPhase 1/Phase 2Dec 30, 2020
- NCT04715997Lead sponsorPhase 1/Phase 2Dec 30, 2020
- NCT04810637Lead sponsorPhase 2Nov 1, 2020
Details
- Founded
- Bundang-Gu, KR Jun 1, 1999
- Last known activity
- Aug 1, 2024